Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ever Fortune.AI Co., Ltd. (6841.TWO)
Taichung City, TW
Ever Fortune.AI Co., Ltd. specializes in delivering cloud-based artificial intelligence solutions. Their product portfolio features a bone age evaluation system, which assists clinicians in determining a child's skeletal age and predicting their ultimate adult height. They also offer a sophisticated breast ultrasound tumor categorization system, designed to empower medical practitioners in tumor diagnosis and facilitate non-invasive screening to guide breast puncture and biopsy decisions concerning tumor malignancy. Additionally, the company provides a computed tomography-based system for assessing liver cancer metastatic risk, thereby enhancing radiologists' operational efficiency and evaluating the potential for metastasis. Their suite of tools further includes a liver fibrosis assessment system designed to measure liver scarring, and an atrial fibrillation detection system that interprets electrocardiogram signals to evaluate the heart's condition. Headquartered in Taichung City, Taiwan, Ever Fortune.AI Co., Ltd. operates as a subsidiary of An Ji Biomedical Corporation.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.84% | -2.12% | +1.52% | -7.68% | -8.10% | -14.27% | -18.12% | -38.74% | -70.10% | -70.10% | -70.10% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+12.2% ★ Q1'26: -3.6% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+187.1% ★ Q1'26: +44.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-3.6% Q1'26: +6.5% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+9.3% Q1'26: +6.5% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+2.3% Q1'26: +1.3% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+25.0% Q1'26: -17.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.18× ★ Q1'26: 0.35× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
93.98M
est: 88.99M (+5.6%)
|
337.52M
est: 337.52M (+0.0%)
|
378.81M
est: 336.00M (+12.7%)
|
447.00M
447.00M – 447.00M
+33.0% YoY
|
932.33M
932.33M – 932.33M
+108.6% YoY
|
| EBITDA |
-16.92M
est: -16.86M (-0.4%)
|
78.64M
est: -63.93M (+223.0%)
|
35.38M
est: 9.84M (+259.6%)
|
13.09M
13.09M – 13.09M
+33.0% YoY
|
27.29M
27.29M – 27.29M
+108.6% YoY
|
| EBIT |
-45.07M
est: -23.34M (-93.1%)
|
56.74M
est: -88.52M (+164.1%)
|
35.38M
est: -14.65M (+341.5%)
|
-19.49M
-19.49M – -19.49M
-33.0% YoY
|
-40.65M
-40.65M – -40.65M
-108.6% YoY
|
| Net Income |
-42.04M
|
30.31M
est: -20.28M (+249.5%)
|
107.40M
est: 59.13M (+81.6%)
|
301.68M
301.68M – 301.68M
+410.2% YoY
|
718.00M
718.00M – 718.00M
+138.0% YoY
|
| SGA |
73.25M
est: 198.39M (-63.1%)
|
128.99M
est: 752.42M (-82.9%)
|
—
est: 190.86M (-100.0%)
|
253.91M
253.91M – 253.91M
+33.0% YoY
|
529.59M
529.59M – 529.59M
+108.6% YoY
|
| EPS |
-0.44
|
0.31
est: -0.21 (+247.6%)
|
0.89
est: 0.49 (+81.6%)
|
2.50
2.50 – 2.50
+410.2% YoY
|
5.95
5.95 – 5.95
+138.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ti-Hao Wang | Chief Technology Officer and Director of Research & Development | 4M | — |
| Ming-Feng Chen | GM & Chairman | 4M | male |
| Donald Lin | Chief Information Security Officer - Division of Platform & Business | — | — |
| En-De Liao | Director of Marketing & Business | — | — |
| Yu-Cheng Li | Chief of Staff & General Manager's Office | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6841.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
